Use of Oral JAK Inhibitors and a TYK2 Inhibitor in the Treatment of Psoriasis–Eczema Overlap ( PsEma ): A Retrospective Study

Key Points

• The study aims to evaluate the effectiveness of JAK and TYK2 inhibitors for treating psoriasis-eczema overlap.
• Retrospective analysis of patient records
• Assessment of treatment outcomes with JAK and TYK2 inhibitors
• Comparison of symptom improvement scores
• Positive trends observed in symptom reduction
• Improvement noted in skin lesion severity
• Increased patient satisfaction with treatment outcomes